SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Catheter Precision, Inc.

Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a 9.99% beneficial ownership stake in Catheter Precision, Inc., holding 1,000,849 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 3 to Schedule 13G.
• The filing indicates beneficial ownership of 1,000,849 shares of Catheter Precision, Inc. common stock.
• This ownership represents 9.99% of the company's outstanding common stock.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the securities.
• Both reporting persons share voting and dispositive power over all 1,000,849 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13G) disclosing beneficial ownership. It does not contain qualitative statements or financial performance data that would indicate a positive or negative sentiment, thus it is neutral.

Positives

• The disclosure of a significant 9.99% stake by an institutional investor like Armistice Capital may signal confidence in Catheter Precision, Inc.'s long-term prospects.
• The passive nature of the 13G filing indicates that the investor is not seeking to influence or control the company, suggesting a belief in current management and strategy.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance from Catheter Precision, Inc. or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of a significant passive investment in a publicly traded company within the healthcare technology sector. It reflects an investment firm's portfolio allocation rather than a direct operational or strategic update from the issuer.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may influence market perception and potentially share price, signaling investor confidence.

Key Dates

Keywords

Catheter Precision, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Healthcare Technology